TriSalus Life Sciences Q2 2025 Earnings Call Set for August 12

TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Positive)

Tags

conferences earnings

07/29/2025 - 04:05 PM

Conference Call and Webcast Scheduled for Tuesday August 12, 2025 at 4:30 PM

WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (鈥淭riSalus鈥� or the 鈥淐ompany鈥�), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy, announced today that it will host a conference call and webcast on Tuesday August 12, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2025. A press release detailing the results will be issued prior to the call.

Parties interested in participating by phone should register using this . After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. The event will also be webcast live on the of TriSalus鈥� website. A replay will also be available on the website following the event.

About TriSalus Life Sciences

TriSalus Life Sciences庐 is a growing, oncology focused medical technology business bringing disruptive drug delivery technology with the goal of improving therapeutic delivery for the treatment of both oncologic and non-oncologic conditions. Additionally, we are exploring the integration of our technology with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications. We have developed an innovative organ-specific platform that is designed to overcome two of the most significant challenges that prevent optimal delivery and performance of therapeutics in these difficult-to-treat diseases: (i) high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii) the immunosuppressive properties of liver and pancreatic tumor immune cells. By systematically addressing these barriers, we aim to improve response to therapies and to enable improved patient outcomes.

In partnership with leading cancer centers across the country 鈥� and by leveraging deep immuno-oncology expertise and inventive technology development 鈥� TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at and follow us on and .